Yahoo Finance

Immix Biopharma’s NXC-201 NEXICART-2 Clinical Trial Data Selected for Oral Presentation at ASCO 2025

LOS ANGELES, April 23, 2025 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or ”IMMX”), a clinical-stage biopharmaceutical company developing cell therapies for AL ...
Yahoo Finance

Immix Biopharma Presents Positive NXC-201 Clinical Data at 66th American Society of Hematology (ASH) Annual Meeting in 16 Relapsed/Refractory AL Amyloidosis Patients

75% (12/16) complete response rate observed in relapsed/refractory AL Amyloidosis patients with median 4 prior lines of therapy LOS ANGELES, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc.
Nasdaq

Immix Biopharma Reports 70% Complete Response Rate for NXC-201 in Phase 1/2 AL Amyloidosis Trial at ASCO 2025

Immix Biopharma announced significant results from its NEXICART-2 Phase 1/2 clinical trial of NXC-201 at the ASCO 2025 conference, achieving a complete response (CR) rate of 70% in patients with ...
Mena FN

Immix Biopharma To Host KOL Event To Discuss NXC-201 Clinical Data Presented At ASCO 2025 In Relapsed/Refractory AL Amyloidosis

LOS ANGELES, CA, May 21, 2025 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”,“Company”,“We” or“Us” or”IMMX”), clinical-stage biopharmaceutical company developing cell therapies for AL ...
Nasdaq

Immix Biopharma Reports Class-Leading Safety Profile for CAR-T NXC-201 in Low-Volume AL Amyloidosis, On Track for BLA Submission

Absence of neurotoxicity of any grade in low-volume disease to-date highlights a significant safety profile for NXC-201, which is crucial for patient acceptance and regulatory approval. Company is on ...